Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2

Stock Information for Immix Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Immix Biopharma Inc.

Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.